FDA approves Livsayis (cemdisiran) as first siRNA therapy in generalized myasthenia gravis
FROM THE WIRE · GLOBENEWSWIRE.COM
Approval based on Phase 3 NIMBLE results demonstrating rapid, deep and sustained disease control that is maintained throughout three-month dosing intervals
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA new drug approval with quarterly dosing may strengthen Regeneron's commercial prospects.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Livsayis is FDA approved as the first and only siRNA therapy for generalized myasthenia gravis.
- 02It is the only treatment with four-times-a-year subcutaneous dosing.
- 03The approval is based on Phase 3 NIMBLE results.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets